ivermectin oral News - LARVOL Sigma

|||||||||| moxidectin / Generic mfg., ivermectin oral / Generic mfg.
Journal: MOXIDECTIN AND IVERMECTIN INHIBIT SARS-COV-2 REPLICATION IN VERO E6 CELLS BUT NOT IN HUMAN PRIMARY AIRWAY EPITHELIUM CELLS. (Pubmed Central) - Jan 26, 2022
These disappointing results call for a word of caution in the interpretation of anti-SARS-CoV-2 activity of drugs solely based on Vero cells. Altogether, these findings suggest that, even by using a high-dose regimen of ivermectin or switching to another drug in the same class are unlikely to be useful for treatment against SARS-CoV-2 in humans.

|||||||||| ivermectin oral / Generic mfg.
Journal: Bacteriome Diversity of Blackflies' Gut and Association with Onchocerca volvulus, the Causative Agent of Onchocerciasis in Mbam Valley (Center Region, Cameroon). (Pubmed Central) - Jan 26, 2022
Blackfly native bacteria are then potentially involved in infection by O. volvulus, either by facilitating or preventing the parasite infestation of the vector. These bacteria represent an interesting potential as a biological tool/target for a novel approach of vector control to fight onchocerciasis.

|||||||||| ivermectin oral / Generic mfg.
Review, Journal: COVID-19 drugs in aquatic systems: a review. (Pubmed Central) - Jan 26, 2022
The outbreak of the human coronavirus disease 2019 (COVID-19) has induced an unprecedented increase in the use of several old and repurposed therapeutic drugs such as veterinary medicines, e.g. ivermectin, nonsteroidal anti-inflammatory drugs, protein and peptide therapeutics, disease-modifying anti-rheumatic drugs and antimalarial drugs, antiretrovirals, analgesics, and supporting agents, e.g. azithromycin and corticosteroids...Degradation mechanisms and metabolite toxicity are poorly known. Potential risks include endocrine disruption, acute and chronic toxicity, disruption of ecosystem functions and trophic interactions in aquatic organisms, and the emergence of antimicrobial resistance.

|||||||||| ivermectin oral / Generic mfg.
Observational data, Journal: Ivermectin Prophylaxis Used for COVID-19: A Citywide, Prospective, Observational Study of 223,128 Subjects Using Propensity Score Matching. (Pubmed Central) - Jan 26, 2022
Potential risks include endocrine disruption, acute and chronic toxicity, disruption of ecosystem functions and trophic interactions in aquatic organisms, and the emergence of antimicrobial resistance. In this large PSM study, regular use of ivermectin as a prophylactic agent was associated with significantly reduced COVID-19 infection, hospitalization, and mortality rates.

|||||||||| ivermectin oral / Generic mfg.
Journal: Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud. (Pubmed Central) - Jan 26, 2022
This highlights the need for rigorous quality assessments, for authors to share patient-level data, and for efforts to avoid publication bias for registered studies. These steps are vital to facilitate accurate conclusions on clinical treatments.

||||||||||  metformin / Generic mfg., ivermectin oral / Generic mfg., fluvoxamine / Generic mfg.
Trial completion date:  COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) -  Jan 26, 2022
P3, N=1350, Recruiting,  Sponsor: University of Minnesota
These steps are vital to facilitate accurate conclusions on clinical treatments. Trial completion date: Dec 2021 --> Feb 2023